BPH Global Moves to Prototype Stage in Fucoidan Supplement with BRIN Partnership

Advancing Fucoidan Extraction and Supplement Development

BPH Global Ltd (ASX:BP8) has officially progressed to Stage 2 in its partnership with Indonesia’s National Research and Innovation Agency (BRIN), marking a shift from initial framework collaboration to active project execution. The focus is on developing fucoidan extraction technology and creating a powdered fucoidan supplement prototype designed for food and beverage applications.

This move follows the binding Memorandum of Understanding signed in February 2026 and is formalised through a Cooperation Agreement and detailed Terms of Reference. The project aims to scale extraction processes to a 10kg input level, standardise quality, and produce a prototype that could underpin future commercial products.

Modest Funding with Strategic Implications

The Stage 2 project is valued at approximately IDR 207.9 million (around A$20,800), with BPH Global contributing roughly A$14,600 in cash-funded components including raw materials, labour, and equipment rental. BRIN provides in-kind laboratory testing and analysis valued at about A$6,200. While the financial scale is modest, the collaboration leverages BRIN’s registered intellectual property on fucoidan extraction technology, aiming to build Indonesia’s capacity to produce fucoidan domestically and reduce import reliance.

The project’s outputs are expected to include a fucoidan extract prototype, draft intellectual property outcomes, and development of fucoidan as a nutraceutical raw material. This aligns with Indonesia’s broader research down streaming strategy, which BRIN spearheads to convert public research into commercially viable technologies.

Timeline and Commercialisation Pathway

Work under Stage 2 is set to commence imminently, with a prototype targeted within approximately three months. Success in this proof-of-concept phase will prompt assessment of the technology’s technical and commercial viability, potentially leading to licensing discussions and progression to a Stage 3 commercialisation phase governed by separate agreements.

This development complements BPH Global’s recent expansion efforts, including securing a 3.4-hectare seaweed cultivation site near Makassar to bolster its Indonesian footprint and supply chain integration. The company’s multi-pronged approach to seaweed-based products, from nutraceuticals to biofuels, reflects a strategic push to capitalise on Indonesia’s marine bioindustry potential.

Given the early stage and relatively small project scale, the commercial impact remains uncertain, but the collaboration with BRIN positions BPH Global to potentially lead in fucoidan supply within the region, tapping into growing global demand for functional food ingredients and supplements.